Marina Cooney, MD
Psychiatry · Bryn Mawr, PANPI 1982683207
Payments from drug & device makers
Across 34 payments — averaging $19.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$136
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$132
- Otsuka America Pharmaceutical, Inc.$106
- AbbVie$64
- Idorsia Pharmaceuticals US Inc$51
- Corium, LLC$50
- plus $111 from 4 others
What the payments were for
- Food & beverage$651100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 6 | $136 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 6 | $132 |
| Otsuka America Pharmaceutical, Inc. | 6 | $106 |
| AbbVie | 4 | $64 |
| Idorsia Pharmaceuticals US Inc | 3 | $51 |
| Corium, LLC | 4 | $50 |
| Teva Pharmaceuticals USA, Inc. | 2 | $47 |
| Jazz Pharmaceuticals Inc. | 1 | $23 |
| Neurocrine Biosciences, Inc. | 1 | $21 |
| Neos Therapeutics, LP | 1 | $20 |
How this compares
$651 in reported general payments places this provider in the 70th percentile of 1,838 psychiatry providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 30 | $2,162 |
| Duloxetine Hcl | 28 | $1,455 |
| Buspirone Hcl | 60 | $1,030 |
| Olanzapine | 36 | $891 |
| Aripiprazole | 39 | $861 |
| Quetiapine Fumarate | 41 | $829 |
| Bupropion XlBupropion Hcl | 39 | $764 |
| Escitalopram Oxalate | 52 | $730 |
| Gabapentin | 25 | $470 |
| Trazodone Hcl | 48 | $446 |
| Haloperidol Decanoate | 14 | $430 |
| Clonazepam | 67 | $409 |
| Mirtazapine | 20 | $369 |
| Lamotrigine | 21 | $355 |
| Citalopram HbrCitalopram Hydrobromide | 28 | $306 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Bryn Mawr
- Cherian VergheseNorristown$16.3M
- Steven ArnoldPhiladelphia$4.1M
- Paul GrossAllentown$4.1M
- Shivkumar HattiMedia$4M
- Rebecca RomaPittsburgh$3.3M
- Matthew BergerMoosic$2.4M
- Michael ThasePhiladelphia$2.2M
- Robert NelsonWyomissing$2.2M
- Mark MattaNew Castle$847K
- Mayer AyyashPittsburgh$714K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.